tandemdiabetes
Tandem Diabetes slides hard on growing insulin cartridge recall
Diabetes: Tandem recalls insulin cartridges over leak risk
Tandem Diabetes closes $138M IPO
Tandem Diabetes Care (NSDQ:TNDM) closed its initial public offering yesterday after selling all 9.2 million shares on offer for $15 apiece, raising $138 million.
Underwriters add $18M to Tandem Diabetes IPO
Tandem Diabetes Care (NSDQ:TNDM) said today that the underwrites of its initial public offering picked up a 1.2 million-share over-allotment at $15 per share, adding $18 million to the IPO’s value.
UPDATE: Tandem Diabetes shares close 28% above IPO price
Shares of Tandem Diabetes Care (NSDQ:TNDM) closed up some more than 28% above their offering price today after the medical device company’s initial public offering debuted on the NASDAQ exchange.
BREAKING: Tandem Diabetes shares surge 30% above IPO price
Shares of Tandem Diabetes Care (NSDQ:TNDM) are up some 30% today after the medical device company’s initial public offering debuted on the NASDAQ exchange.
Tandem Diabetes prices $120M IPO
Tandem Diabetes Care is set to begin trading on the NASDAQ stock exchange today after pricing its initial public offering of 8 million shares at $15 each, the upper end of its initial range.
The amount the company actually raised could be higher than the $120 million pricing due to a 1.2 million-share over-allotment for the offering’s underwriters, which if exercised would push the raise to $138 million. Shares are expected to begin trading today under the TNDM symbol.
Tandem Diabetes details venture-backed $123M IPO
Tandem Diabetes Care upped the ante on its venture-backed initial public offering, increasing its maximum aggregate price to $123.2 million and pricing shares at between $13-$15 apiece.
The company, maker of the touch-screen t:slim insulin delivery system, will begin trading on the Nasdaq exchange under the ticker ‘TNDM’ following the IPO.
Tandem Diabetes files for IPO of up to $100M
Tandem Diabetes Care this week filed registration documents ahead of an initial public offering that the San Diego company estimated may be worth up to $100 million. Tandem shares will be listed on the Nasdaq exchange under the ticker ‘TNDM’.
The registration has not yet become effective, according to the company.
Tandem Diabetes Care wins FDA clearance for new pump software
Tandem Diabetes Care won FDA clearance for its new web-based software, called t:connect, a PC- and Mac-compatible program designed for use with Tandem’s touch-screen t:slim insulin pump.